Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
NCT05028972 · View on ClinicalTrials.gov ↗
Study Summary
HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff can implement this program and achieve similar results. The second part will give ED staff increasing levels of responsibility for screening Veterans for hearing difficulty and providing personal amplifiers when such difficulty is detected.
Conditions Studied
Interventions
- OTHER Personal Amplifier
- OTHER No Personal Amplifier
Study Locations (6)
New York
- VA NY Harbor Healthcare System, New York, NY — New York
- Syracuse VA Medical Center, Syracuse, NY — Syracuse
- James J. Peters VA Medical Center, Bronx, NY — The Bronx
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO — Aurora
North Carolina
- Durham VA Medical Center, Durham, NC — Durham
Texas
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX — Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,050 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05028972
The ClinicalTrials.gov registry entry for NCT05028972 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,863 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions — of which Personal Amplifier is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05028972 reports 6 study locations spanning 4 distinct geographic areas — top geographies include New York, Colorado, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05028972 about?
NCT05028972 is a clinical study titled "Hearing Impairment, Strategies and Outcomes in VA Emergency Departments". HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance und...
What is the current status of trial NCT05028972?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,050 participants. The study started on 2021-12-08. Estimated completion is 2026-09-30.
What conditions does trial NCT05028972 study?
This clinical trial studies the following conditions: Hearing Loss, Hospital Readmission, Emergency Service. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05028972?
The interventions under investigation include: Personal Amplifier (OTHER), No Personal Amplifier (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05028972?
This trial is sponsored by VA Office of Research and Development, which has 1,863 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05028972 being conducted?
This trial has 6 study locations across Colorado, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.